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Detection of Soluble
Angiotensin-Converting Enzyme 2 in Heart Failure
Insights Into the Endogenous Counter-Regulatory
Pathway of the Renin-Angiotensin-Aldosterone System
Slava Epelman, MD, PHD,* W. H. Wilson Tang, MD, FACC,†‡ Stephen Y. Chen, MD,*
Frederick Van Lente, PHD,‡ Gary S. Francis, MD, FACC,† Subha Sen, PHD, DSC§
Cleveland, Ohio
Objectives We sought to determine whether circulating soluble angiotensin-converting enzyme 2 (sACE2) is increased in the
plasma of patients with heart failure (HF).
Background Angiotensin-converting enzyme 2 (ACE2) is an integral membrane protein that antagonizes the actions of
angiotensin II and prevents the development of HF in animal models. However, because of the need for in-
vasive cardiac tissue sampling, little is known about whether ACE2 is involved in the pathophysiology of HF
in humans.
Methods We developed a sensitive and specific assay to measure sACE2 activity in human plasma and screened a het-
erogeneous group of patients suspected of having clinical HF.
Results Increasing sACE2 plasma activity strongly correlated with a clinical diagnosis of HF (p  0.0002), worsening left
ventricular ejection fraction (p  0.0001), and increasing B-type natriuretic peptide levels (p  0.0001). Similar
to B-type natriuretic peptide, sACE2 activity reflected the severity of HF, with increasing levels associated with
worsening New York Heart Association functional class (p  0.0001). These associations were independent of
other disease states and medication use. We found that sACE2 activity was increased in patients with both isch-
emic and nonischemic cardiomyopathies and also in patients with clinical HF but a preserved left ventricular
ejection fraction.
Conclusions Soluble ACE2 activity is increased in patients with HF and correlates with disease severity, suggesting that a car-
dioprotective arm of the renin-angiotensin-aldosterone system is active in HF. (J Am Coll Cardiol 2008;52:
750–4) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.02.088(
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nlthough the pathophysiology of heart failure (HF) is
omplex, an important final common pathway involves the
ctivation of the renin-angiotensin-aldosterone system
RAAS). Angiotensin-converting enzyme (ACE) mediates
See page 755
he cleavage of angiotensin (Ang) I into Ang II, a peptide
hat acts downstream on specific angiotensin type I (AT-1)
eceptors, which together are all important targets for
odern HF therapeutics. Angiotensin-converting enzyme 2
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008, accepted February 26, 2008.ACE2) is a recently discovered homolog and, in contrast to
ther members of RAAS, ACE2 is seemingly protective in
F (1). It is an integral membrane carboxypeptidase that
emoves the terminal amino-acid from Ang II, resulting in
he production of a biologically active peptide, Ang(1-7),
hat antagonizes the effects of Ang II by activating the Mas
eceptor (2,3). Mice that are deficient in ACE2 have
ncreased Ang II levels and a severe cardiac contractility
efect that is reversed by the genetic deletion of ACE (4).
ntracardiac overexpression of ACE2 prevents Ang II-
nduced hypertension and cardiac fibrosis, implicating a
irect in vivo cardioprotective role for ACE2, in addition to
uggesting possible therapeutic utility (5).
ACE2 gene expression is increased in tissue samplesfrom
atients with left ventricular dysfunction (6). Traditionally,
CE2 has been thought to be tissue bound and, as a result, the
eed for invasive cardiac tissue sampling has limited additional
linical studies. Herein, we examine the feasibility of detecting
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uman plasma. We then hypothesized that the endogenous
egulatory arm of the RAAS, as measured by sACE2, would
e increased in patients with HF.
ethods
CE2 enzymatic assay. The ACE2-specific quenched
uorescent substrate protocol was performed as previously
escribed with modifications (7). Human plasma (Biorec-
amation, Hicksville, New York), and patients’ plasma
amples were diluted in a ratio of 30:70 with enzyme buffer
1 mol/l NaC1, 75 mmol/l Tris-HCl, 5 mmol/l ZnCl2, pH
.5) in the presence of protease inhibitors, including capto-
ril 10 mol/l, amastatin 5 mol/l, bestatin 10 mol/l (all
rom Sigma Chemical Co., St. Louis, Missouri), and
-Pro-prolinal 10 mol/l (Biomol International, L.P.,
lymouth Meeting, Pennsylvania). Samples were incubated
ith quenched fluorescent substrate diluted in enzyme buffer
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Figure 1 Plasma ACE2 Enzymatic Assay Specificity
(A) rACE2 (25 ng/ml) was mixed with 30% commercial human plasma in the
presence of different concentrations of the specific ACE2 inhibitor DX600, and
ACE2 activity was determined after incubation for 18 h. Data are expressed as
the percentage of ACE2 activity of rACE2. (B) Thirty percent human plasma
(patient sample) was pre-incubated with either DX600 (1 mol/l), anti-human
ACE2 polyclonal antibody, or isotype-matched control antibodies for 30 min and
then ACE2 activity was determined at 4 and 18 h. One of 3 representative
experiments is shown. ACE  angiotensin-converting enzyme; IgG  immuno-
globulin G; rACE2  recombinant angiotensin-converting enzyme 2 activity;
SACE  soluble angiotensin-converting enzyme.tfinal concentration 50 mol/l,
00 l) at 37°C. Maximal fluores-
ence (SpectraMax GeminiXS,
olecular Devices, Wokingham,
nited Kingdom) was determined
y experimentation (ex  324
m, em  430 nm, using a
20-nm cutoff filter). Specificity
as determined by pre-incubating
lasma for 30 min with either the
pecific human ACE2 inhibitor
X600 (Phoenix Pharmaceuti-
als, Burlingame, California) (8),
nti-ACE2 polyclonal antibod-
es, or control polyclonal anti-
odies (R&D Systems, Inc.,
inneapolis, Minnesota). Each
atient’s plasma sACE2 activity was determined at 18 h,
ith 1 h as the baseline. Values were normalized to a
ecombinant ACE2 standard curve (R&D Systems). Intra-
ssay variability was 6.1  1.7%, and interassay variability
as 20.6  5.5%. DX600 was subsequently used in the
ssays for patient samples.
atient sample collection. This study received institu-
ional review board approval. Plasma samples (n  228)
ere obtained from any subject suspected of having clinical
F and had a measured B-type natriuretic peptide (BNP)
ADVIA assay, Siemens Corporation, New York, New
ork) at the Cleveland Clinic between March and August
006. We excluded patients who had congenital heart
iseases, with acute coronary syndromes, or who were in the
ost-operative setting. Manual chart review was then per-
ormed by a physician blinded from the analysis to adjudi-
ate both the presence of HF and its severity. Clinical,
chocardiographic (within 100 days of sample isolation,
ncluding left ventricular ejection fraction [LVEF] assess-
ent using biplane Simpson’s rule), and biochemical char-
cteristics and demographics were determined before data-
ase closure and blinding and before sample analysis.
tatistical analysis. Univariate analyses were conducted
ith the Student t test or chi-square test between groups
nd 1-way analysis of variance among sACE2 interquartile
ange for the various clinical parameters. Logistic regression
nalysis was performed to assess for confounding variables.
tepwise analysis was also performed in each of the models
sed (probability to enter or leave  0.10), which yielded
esults similar to those presented. Missing data were left
nassigned during the analysis (did not exceed n 8 for any
ariable). All statistical analysis was performed with JMP
.0.2 (SAS Institute, Cary, North Carolina). A p value
0.05 was considered significant.
esults
ACE2 activity measurement. The specific ACE2 inhibi-
Abbreviations
and Acronyms
ACE2  angiotensin-
converting enzyme 2
Ang  angiotensin
BNP  B-type natriuretic
peptide
HF  heart failure
NYHA  New York Heart
Association
RAAS  renin-angiotensin-
aldosterone system
sACE2  soluble
angiotensin-converting
enzyme 2or DX600 (8) inhibited recombinant ACE2 activity in a
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Soluble ACE2 in HF August 26, 2008:750–4ose-dependent fashion (Fig. 1A). Both DX600 (1 mol/l)
nd a polyclonal anti-ACE2 antibody (8 g/ml) inhibited
ACE2 activity in human plasma samples, demonstrating
he observed increase in fluorescence was attributable spe-
ifically to sACE2 activity (Fig. 1B). Soluble angiotensin-
onverting enzyme 2 activity was inhibited by DX600 in
atient Demographics
Table 1 Patient Demographics
Variables
Suspected HF
HF Present by
Adjudication
(n  159)
No HF by
Adjudication
(n  69)
Mean age  SD (yrs) 63.1 14 59.1 13
Men (%) 68 62
Mean LVEF  SD (%) 34 17* 57 7
Mean BNP  SD (pg/ml) 403 552* 75 80
Comorbid conditions
Hypertension (%) 67%† 35%
Diabetes (%) 34%† 5%
Atrial fibrillation (%) 35% 64%†
Coronary artery disease (%) 54%† 19%
Creatinine  SD (mg/dl) 1.3 0.95* 1.02 0.88
Medication use (%)
ACE inhibitor 60%† 28%
Beta-blocker 72%† 50%
ARB 21% 13%
Loop diuretic 75%† 17%
Aldosterone antagonist 36%† 7%
Digoxin 38%† 12%
p  0.001, Student t test. †p  0.001, chi-square test.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BNP  B-type
atriuretic peptide; HF  heart failure; LVEF  left ventricular ejection fraction.
Clinical Characteristics Based on Quartile Plasm
Table 2 Clinical Characteristics Based on Q
Variable* sACE2 Quartile 1 s
sACE2 (ng/ml) 16.6
Age (yrs) 58.4 (54.8–62.1)
Gender (% male) 50.9
HF (%) 54.4
Ischemic CM (%) 42.0
LVEF (%) 48.9 (44.4–53.5)
BNP (pg/ml) 161 (42–280)
Creatinine (mg/dl) 1.07 (0.82–1.31)
Comorbid conditions (%)
Coronary artery disease 26.4
Hypertension 54.4
Diabetes 22.8
Atrial fibrillation 40.4
Medications (%)
Aldosterone antagonist 21.1
Loop diuretic 43.9
Beta-blocker 63.2
ACE inhibitor 49.1
ARB 15.8
*Continuous variables expressed as the mean (95% confidence interv
variables.
CM  cardiomyopathy; sACE  soluble angiotensin-converting enzyme; othommercially available plasma, indicating the ubiquitous
asal expression of sACE2 (13.7  3.6 ng/ml).
tudy population and sACE2 activity. In the study co-
ort, 70% had a clinical diagnosis of HF (cases), and 30%
howed no biochemical or clinical evidence of HF (controls)
Table 1). Plasma sACE2 activity was stratified by quartiles.
ncreasing sACE2 activity was strongly correlated with a
iagnosis of HF, irrespective of etiology, and was not
ssociated with any other disease state (Table 2). The odds
atio of predicting HF with sACE2 values above the fourth
uartile was 4.8 (2.0 to 11.9, p  0.0002, Fisher exact test).
oluble ACE2 activity also was associated with a worsening
VEF, increasing BNP levels, and use of loop diuretics
Table 2). The association between sACE2 activity and
ldosterone antagonists was more clearly demonstrated by
he use of a direct comparison (sACE2 ng/ml, 95% confi-
ence interval [absence vs. presence of aldosterone antago-
ists]: 29.6 [26.2 to 32.9] vs. 39.3 [34.0 to 44.7], p 
.0025, analysis of variance). In logistic regression analysis,
ACE2 activity was independently associated with the
resence of HF (Table 3).
eterminants of sACE2 activity. Greater sACE2 activity
as associated with worsening New York Heart Association
NYHA) functional class (Fig. 2). Using logistic regression
nalysis, we found sACE2 activity to be independently asso-
iated with increasing NYHA functional class (p 0.023) and
og-transformed BNP (p 0.003) and was inversely associated
ith LVEF (p  0.023). Aldosterone antagonists were the
nly class of medication found to independently associate with
ACE2 plasma activity (chi-square  4.2, p  0.040).
CE2 Activity
le Plasma sACE2 Activity
Quartile 2  3 sACE2 Quartile 4 p Value†
6.6–41.1 41.1 —
(60.2–65.3) 63.7 (60.0–67.3) 0.09
69.6 75.0 0.014
67.8 89.3 0.0002
44.4 40.4 NS
(38.0–44.3) 32.0 (27.4–36.6) 0.0001
(147–315) 601 (480–721) 0.0001
(1.06–1.40) 1.46 (1.21–1.71) 0.08
36.5 51.2 0.14
53.0 69.6 0.10
25.2 26.7 0.88
40.0 55.4 0.14
25.2 39.3 0.07
52.2 82.1 0.0001
66.1 64.2 0.92
50.4 51.8 0.96
20.1 17.9 0.78
alysis of variance across sACE2 quartiles, chi-square test for nominala sA
uarti
ACE2
1
62.7
41.1
231
1.23
al). †Aner abbreviations as in Table 1.
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nderstanding the relationship between ACE2, cardiac cell
rowth, fibrosis, and remodeling may help us better under-
tand the protective RAAS pathways involved in HF.
espite many elegant animal studies, there is a relative
aucity of knowledge about whether ACE2 physiology is
elevant in humans. Herein, we present 3 important obser-
ations in human HF: 1) sACE2 activity can be readily
easured in heterogeneous patient populations; 2) sACE2
ctivity is elevated in human HF; and 3) sACE2 activity
orrelates independently with worsening disease severity as
efined by LVEF and NYHA functional class.
One of the most intriguing questions our study raises is
hat role ACE2 plays in HF progression. Similar to its
ounterpart ACE, ACE2 is an integral membrane protein
ith a signal peptide and an N-terminal transmembrane
omain. The presence of circulating ACE2 in plasma
ndicates either the cause or effect of an adaptive or
aladaptive physiologic process operative in human HF.
nlike ACE, it is known that cleavage of membrane ACE2
nto the soluble form is in part dependent on the tumor
ecrosis factor- convertase ADAM17, a protease up-
egulated in HF (9,10). Up-regulation of proinflammatory
ytokines and activation of proteases during HF has long
een implicated as a pathologic mechanism of cardiac
emodeling (9,11). Therefore, cleavage of membrane ACE2
ay be due to the up-regulation of a pathological protease,
esulting in a relative decrease in local membrane ACE2
evels and cardiac dysfunction. Alternatively, cleavage and
elease of membrane ACE2 as a soluble form may offer a
ompensatory mechanism in HF. Angiotensin 1-7 has a
ery short half-life (9 s), and release of sACE2 from the
ascular endothelium may serve to alter systemic Ang(1-7)
nivariate and Multivariate HFrediction Model Based on Plasma sACE2 Activity
Table 3 Univariate and Multivariate HFPrediction Model Based on Plasma sACE2 Activity
Variable OR (95% CI) p Value
sACE2 41.1 (ng/ml) 4.8 (2.0–11.9) 0.0001
Adjusted for age (yrs) 4.7 (2.0–12.8) 0.0001
Adjusted for gender (% male) 4.7 (2.1–12.9) 0.0001
Adjusted for LVEF (%) 4.9 (1.6–18.0) 0.009
Adjusted for BNP 100 (pg/ml) 3.1 (1.3–8.7) 0.03
Adjusted for creatinine (mg/dl) 4.2 (1.8–11.5) 0.002
Adjusted for coronary artery disease 4.6 (1.9–12.8) 0.001
Adjusted for hypertension 4.3 (1.8–11.8) 0.002
Adjusted for atrial fibrillation 6.9 (2.8–19.4) 0.0001
Adjusted for aldosterone antagonists 4.3 (1.8–11.9) 0.002
Multivariable model: limited*
sACE2 41.1 (ng/ml) 4.2 (1.3–15.7) 0.03
Multivariable model: full†
sACE2 41.1 (ng/ml) 6.4 (1.5–32.2) 0.02
Parameters included in the limited clinical model include age, gender, BNP 100 ng/ml, LVEF,
nd creatinine. †Parameters included in the full model include those in the limited model in
ddition to the use of loop diuretics, aldosterone antagonists, ACE inhibitors and ARBs, and the
resence of atrial fibrillation, diabetes mellitus, hypertension, and coronary artery disease.o
CI confidence interval; OR odds ratio; sACE soluble angiotensin-converting enzyme; other
bbreviations as in Table 1.oncentrations and the relative peripheral balance of ACE2/
CE. By demonstrating the relationship between greater
evels of sACE2 activity and HF, these data give us insights
nto the systemic activation of an endogenous counter-
egulatory pathway beyond its membrane-bound confine-
ents.
ACE2 expression can be modulated through a variety of
echanisms. Aldosterone decreases ACE2 transcription
hrough a nicotinamide adenine dinucleotide phosphate
xidase-mediated pathway (12). It is therefore interesting to
bserve the direct correlation between the use of aldosterone
eceptor antagonists and greater sACE2 activity, which is
onsistent with the observation of increased ACE2 produc-
ion from patients treated with spironolactone, indicating a
otential mechanism of their beneficial effects (12). Stimu-
ation through the AT-1 receptor is also known to suppress
CE2 expression (13). However, unlike animal studies,
atients in our study were exposed to long-term inhibition
f the RAAS, which might account for the lack of associ-
tion between plasma sACE2 and the use of either ACE
nhibitors or Ang receptor blockers.
Association between plasma sACE2 activity and plasma
NP provides an objective validation of the association
etween the systemic release of ACE2 and HF severity. As
he detection of sACE2 activity likely signifies the activa-
ion of counter-regulatory mechanisms, the ultimate clinical
tility of measuring sACE2 activity may depend on our
bility to possibly target activation of the ACE2–Ang(1-7)–
as pathway rather than to improve the clinical diagnosis
Figure 2 sACE2 Activity Was Associated
With Worsening NYHA Functional Class
Quartile plots are shown. One-way analysis of variance, p  0.0067. Number
of patients (n) is given for each group. HF  heart failure; NYHA  New York
Heart Association; sACE2  soluble angiotensin-converting enzyme 2 activity.f HF in the acute setting, the latter task in which plasma
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Soluble ACE2 in HF August 26, 2008:750–4NP testing has been well validated to perform. Our data
upport further investigations to better understand the
linical utility and significance of targeting ACE2 pathways
or therapeutic interventions.
onclusions
sing a specific and sensitive assay, soluble ACE2 activity
an be detected in human plasma. Increased soluble ACE2
ctivity is associated with more advanced HF.
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